Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

Zyesami (Aviptadil) COVID-19 Therapeutic Description

Zyesami (Aviptadil) is a formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which the late Dr. Sami first discovered Said in 1970, for whom ZYESAMI™ is named. Because of its lack of toxicity and low cost of manufacture compared to proprietary biologics, VIP may be uniquely attractive to those focused on global countermeasures against COVID-19, says the company.

VIP is known to target the VPAC1 receptor of the alveolar type II cell (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.

https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic

Effective Covid-19 treatments that help protect lungs in hospitalizations and against long-Covid are really in demand. Long Covid-19 can reduce patients to effectively be disabled and even decrease their intelligence with “brain fog” among other symptoms. It’s not clear how grave an effect long covid will have on the global economy in terms of productivity at scale.

Relief focuses primarily on clinical-stage programs based on molecules with a history of clinical testing and use in human patients or a strong scientific rationale. Relief’s lead drug candidate, RLF-100 TM (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP), is in late-stage clinical testing in the U.S. for the treatment of respiratory deficiency due to COVID-19. Zyesami, its commercial name, has turned out to be one of the most effective treatments for serious Covid-19 cases. You can see their website here.

As more countries get EUA for Zyesami it’s only a matter of time until major European countries and the U.S. and other countries in grave danger approve it — like Indonesia, India, Russia, Brazil and others.

https://lastfuturist.com/relief-therapeutics-eua-for-zyesami-expanding-to-more-countries/